Loiasis
11
1
1
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
9.1%
1 terminated out of 11 trials
87.5%
+0.9% vs benchmark
27%
3 trials in Phase 3/4
57%
4 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 7 completed trials
Clinical Trials (11)
Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination
Spontaneous Antigenemia in Loiasis
Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa
Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients
21-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia
A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects
Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events
Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa
Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients
Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis